Faculty Bibliography

BACKGROUND:While survival after acute myocardial infarction has improved substantially, older adults remain at heightened risk for hospital readmissions and death. Evidence for the role of cognitive impairment in older myocardial infarction survivors' risk for these outcomes is limited. METHODS:3041 patients aged ≥75 years hospitalized with acute myocardial infarction (mean age 82 ± 5 years, 56% male) recruited from 94 US hospitals. Cognition was assessed using the Telephone Interview for Cognitive Status; scores of <27 and <22 indicated mild and moderate/severe impairment, respectively. Readmissions and death at 6 months post-discharge were ascertained via participant report and medical record review. Associations between cognition and outcomes were evaluated with multivariable-adjusted logistic regression. RESULTS:Mild and moderate/severe cognitive impairment were present in 11% and 6% of the cohort, respectively. Readmission and death at 6 months occurred in 41% and 9% of participants, respectively. Mild and moderate/severe cognitive impairment were associated with increased risk of readmission (odds ratio [OR] 1.36; 95% confidence interval [CI], 1.08-1.72 and OR 1.58; 95% CI, 1.18-2.12, respectively) and death (OR 2.19; 95% CI, 1.54-3.11 and OR 3.82; 95% CI, 2.63-5.56, respectively) in unadjusted analyses. Significant associations between moderate/severe cognitive impairment and death (OR 1.69; 95% CI, 1.10-2.59) persisted after adjustment for demographics, myocardial infarction characteristics, comorbidity burden, functional status, and depression, but not for readmissions. CONCLUSIONS:Moderate-to-severe cognitive impairment is associated with heightened risk of death in older acute myocardial infarction patients in the months after hospitalization, but not with readmission. Routine cognitive screening may identify older myocardial infarction survivors at risk for poor outcomes who may benefit from closer oversight and support in the post-discharge period.

Background Cardiac rehabilitation (CR) is increasingly being prescribed for adult congenital heart disease (ACHD) patients after cardiac procedures or for reduced exercise tolerance. We aim to describe the functional capacity improvements of ACHD patients in CR. Methods This retrospective study included ACHD patients at NYU Rusk Cardiac Rehabilitation from 2013-2019. We collected data on patient characteristics, number of sessions attended, and exercise testing results. Paired sample t-tests were used to assess for changes between pre- and post-CR exercise time and metabolic equivalents (METs). Results In total, 76 ACHD patients (mean age 38.2 years, 56.6% female, 89.5% moderate or complex conditions by anatomic classification) participated in CR. Referral indication was reduced exercise tolerance for 43.4% and was post-cardiac procedure (transcatheter or surgical) for the remainder. Among 37 patients (48.7%) who finished all 36 CR sessions, complete exercise testing data was available for 29 of them. Exercise time increased by 83.8 seconds (95% CI, 43.9 - 123.8; baseline mean 520.7), METs increased by 1.2 (95% CI, 0.6 - 1.8; baseline mean 8.1), and both parameters increased for 72.4% of these patients. These statistically significant improvements were observed across referral indications. Conclusion On average, CR benefits ACHD patients who complete the program, regardless of referral indication. Efforts to increase CR referral and retention would allow more patients to benefit. [Formula presented]
Copyright

Background Racial disparities in age-associated functional impairments, which are powerful predictors of readmission and mortality after acute myocardial infarction (AMI), have not been described in older AMI patients. Given an aging population and growing recognition of the prognostic value of functional impairments, this is an important knowledge gap. Methods We analyzed data from SILVER-AMI, a prospective cohort study that enrolled patients aged >=75 hospitalized for AMI at 94 sites across the US. Patients were assessed for functional impairments during hospitalization. Patients completed an in-person Telephone Interview for Cognitive Status, a Timed Up and Go test of mobility and a grip strength test. Vision and hearing impairments were self-reported. Patients also reported their prehospital independence in activities of daily living (bathing, dressing, ambulating, rising from a chair). We evaluated racial disparities in functional impairments using Pearson's chi-squared test with Yates' continuity correction. Results Of 3,041 patients, 2,668 (87.7%) identified as white and 325 (10.7%) identified as another race (250 Black, 40 Asian, 15 American Indian or Alaskan Native, 8 Native Hawaiian or Pacific Islander, 12 two or more races). Nonwhite patients were younger (80.9 yr. vs. 81.7 yr.; p<0.01), less likely to have a college degree (35.7% vs. 43.5%; p<0.05) and more often female (59.7% vs. 42.5%; p<0.001). Cognitive impairment was more common among nonwhite patients (35.1% vs. 14.5%; p<0.001), as was mobility impairment (64.3% vs. 54.6%; p<0.001). Weak grip was similarly prevalent in both groups (63.1% vs. 59.4%; p=0.29). Vision impairment was more common among nonwhite patients (50.2% vs. 35.7%; p<0.001), while hearing impairment was less common (38.5% vs. 55.7%; p<0.001). Nonwhite patients were more likely to report a disability in one or more activities of daily living (21.2% vs. 13.0%; p<0.001). Conclusion In this well-characterized AMI cohort, nonwhite patients had a more "geriatric" phenotype despite a younger age, with more functional impairments (cognition, mobility, vision) and a higher rate of disability in one or more activities of daily living.
Copyright

PURPOSE OF REVIEW:The utility of aspirin and statins for primary prevention of atherosclerotic cardiovascular disease remains ambiguous in older adults. Current guidelines and recent data are vague and inconclusive. This review seeks to summarize the landscape of primary prevention of cardiovascular disease in older adults and explore the role of shared decision making. RECENT FINDINGS:Observational data suggest potential benefit of statin therapy in older adults. Aspirin is presently not recommended for primary prevention based on evidence from recent clinical trials. The implementation of shared decision making and decision aids in routine clinical practice remains challenging but may rise in coming years. Clinical trial data on the horizon may aid in solidifying guideline therapy for statin use. However, in the face of uncertainty, shared decision making between provider and patient should be utilized to determine whether pharmacotherapy may benefit older adults. Decision aids are an effective tool to guide this process.

BACKGROUND:We sought to examine whether people with a diagnosis of cardiovascular disease (CVD) experienced a greater incidence of subsequent cognitive impairment (CI) compared to people without CVD, as suggested by prior studies, using a large longitudinal cohort. METHODS:We employed Health and Retirement Study (HRS) data collected biennially from 1998 to 2014 in 1305 U.S. adults age ≥ 65 newly diagnosed with CVD vs. 2610 age- and gender-matched controls. Diagnosis of CVD was adjudicated with an established HRS methodology and included self-reported coronary heart disease, angina, heart failure, myocardial infarction, or other heart conditions. CI was defined as a score < 11 on the 27-point modified Telephone Interview for Cognitive Status. We examined incidence of CI over an 8-year period using a cumulative incidence function accounting for the competing risk of death. RESULTS:Mean age at study entry was 73 years, 55% were female, and 13% were non-white. Cognitive impairment developed in 1029 participants over 8 years. The probability of death over the study period was greater in the CVD group (19.8% vs. 13.8%, absolute difference 6.0, 95% confidence interval 2.2 to 9.7%). The cumulative incidence analysis, which adjusted for the competing risk of death, showed no significant difference in likelihood of cognitive impairment between the CVD and control groups (29.7% vs. 30.6%, absolute difference - 0.9, 95% confidence interval - 5.6 to 3.7%). This finding did not change after adjusting for relevant demographic and clinical characteristics using a proportional subdistribution hazard regression model. CONCLUSIONS:Overall, we found no increased risk of subsequent CI among participants with CVD (compared with no CVD), despite previous studies indicating that incident CVD accelerates cognitive decline.

BACKGROUND/UNASSIGNED:ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) is a pragmatic clinical trial examining high-dose versus low-dose aspirin among patients with cardiovascular disease. ADAPTABLE is leveraging novel approaches for clinical trial conduct to expedite study completion and reduce costs. One pivotal aspect of the trial conduct is maximizing clinician engagement. METHODS/RESULTS/UNASSIGNED:Clinician engagement can be diminished by barriers including time limitations, insufficient research infrastructure, lack of research training, inadequate compensation for research activities, and clinician beliefs. We used several key approaches to boost clinician engagement such as empowering clinician champions, including a variety of clinicians, nurses and advanced practice providers, periodic newsletters and coordinated team celebrations, and deploying novel technological solutions. Specifically, some centers generated electronic health records-based best practice advisories and research dashboards. Future large pragmatic trials will benefit from standardization of the various clinician engagement strategies especially studies leveraging electronic health records-based approaches like research dashboards. Financial or academic "credit" for clinician engagement in clinical research may boost participation rates in clinical studies. CONCLUSION/UNASSIGNED:Maximizing clinician engagement is important for the success of clinical trials; the strategies employed in the ADAPTABLE trial may serve as a template for future pragmatic studies.

OBJECTIVE:To develop a 180-day readmission risk model for older adults with acute myocardial infarction (AMI) that considered a broad range of clinical, demographic and age-related functional domains. METHODS:We used data from ComprehenSIVe Evaluation of Risk in Older Adults with AMI (SILVER-AMI), a prospective cohort study that enrolled participants aged ≥75 years with AMI from 94 US hospitals. Participants underwent an in-hospital assessment of functional impairments, including cognition, vision, hearing and mobility. Clinical variables previously shown to be associated with readmission risk were also evaluated. The outcome was 180-day readmission. From an initial list of 72 variables, we used backward selection and Bayesian model averaging to derive a risk model (N=2004) that was subsequently internally validated (N=1002). RESULTS:Of the 3006 SILVER-AMI participants discharged alive, mean age was 81.5 years, 44.4% were women and 10.5% were non-white. Within 180 days, 1222 participants (40.7%) were readmitted. The final risk model included 10 variables: history of chronic obstructive pulmonary disease, history of heart failure, initial heart rate, first diastolic blood pressure, ischaemic ECG changes, initial haemoglobin, ejection fraction, length of stay, self-reported health status and functional mobility. Model discrimination was moderate (0.68 derivation cohort, 0.65 validation cohort), with good calibration. The predicted readmission rate (derivation cohort) was 23.0% in the lowest quintile and 65.4% in the highest quintile. CONCLUSIONS:Over 40% of participants in our sample experienced hospital readmission within 180 days of AMI. Our final readmission risk model included a broad range of characteristics, including functional mobility and self-reported health status, neither of which have been previously considered in 180-day risk models.

BACKGROUND:Oldest-old patients (≥85 years) constitute half the acute myocardial infarction hospitalizations among older adults and more commonly have atypical presentation, under-treatment and functional impairments. Yet this group has not been well characterized. OBJECTIVES/OBJECTIVE:We characterized differences in presentation, functional impairments, treatments, health status, and mortality among middle-old (75-84 years) and oldest-old patients with myocardial infarction. METHODS:We analyzed data from the ComprehenSIVe Evaluation of Risk Factors in Older Patients with AMI (SILVER-AMI) study that enrolled 3041 patients ≥75 years of age from 94 hospitals across the US between 2013-2016. We performed Cox proportional hazards regression to examine the association between the oldest-old (n=831) and middle-old (n=2210) age categories with post-discharge 6-month case fatality rate adjusting for socio-demographic and clinical variables, and mobility impairment. RESULTS:The oldest-old were less likely to present with chest pain (52.7% vs. 57.7%) as their primary symptom or to receive coronary revascularization (58.1% vs. 71.8) (p<0.01 for both). The oldest-old were more likely to have functional impairments and had higher 6-month mortality compared with the middle-old patients (HR 1.78, 95% CI 1.39-2.28). This association was substantially attenuated after adjusting for mobility impairment (HR 1.29, 95% CI 0.99-1.68). CONCLUSIONS:There is considerable heterogeneity in presentation, treatment and outcomes among older patients with myocardial infarction. Mobility impairment, a marker for frailty, modifies the association between advanced age and treatments as well as outcomes.

OBJECTIVE:Electronic health records (EHRs) have become a common data source for clinical risk prediction, offering large sample sizes and frequently sampled metrics. There may be notable differences between hospital-based EHR and traditional cohort samples: EHR data often are not population-representative random samples, even for particular diseases, as they tend to be sicker with higher healthcare utilization, while cohort studies often sample healthier subjects who typically are more likely to participate. We investigate heterogeneities between EHR- and cohort-based inferences including incidence rates, risk factor identifications/quantifications, and absolute risks. MATERIALS AND METHODS/METHODS:This is a retrospective cohort study of older patients with type 2 diabetes using EHR from New York University Langone Health ambulatory care (NYULH-EHR, years 2009-2017) and from the Health and Retirement Survey (HRS, 1995-2014) to study subsequent cardiovascular disease (CVD) risks. We used the same eligibility criteria, outcome definitions, and demographic covariates/biomarkers in both datasets. We compared subsequent CVD incidence rates, hazard ratios (HRs) of risk factors, and discrimination/calibration performances of CVD risk scores. RESULTS:The estimated subsequent total CVD incidence rate was 37.5 and 90.6 per 1000 person-years since T2DM onset in HRS and NYULH-EHR respectively. HR estimates were comparable between the datasets for most demographic covariates/biomarkers. Common CVD risk scores underestimated observed total CVD risks in NYULH-EHR. DISCUSSION AND CONCLUSION/CONCLUSIONS:EHR-estimated HRs of demographic and major clinical risk factors for CVD were mostly consistent with the estimates from a national cohort, despite high incidences and absolute risks of total CVD outcome in the EHR samples.

BACKGROUND: Skilled nursing facilities (SNFs) are common destinations after hospitalization for patients with heart failure (HF). However, readmissions from SNFs and immediately after SNF discharge are common. In this study, we examined whether patients with a primary hospital discharge diagnosis of HF may benefit from a HF disease management program (HF-DMP) while undergoing post-acute rehabilitation in SNFs.
METHOD(S): This is a sub-group analysis of a cluster-randomized controlled trial of HF-DMP vs usual care (UC) for patients in SNF (n=671) with a HF diagnosis, regardless of ejection fraction (EF), conducted in 47 SNFs in the Denver-metropolitan area. The HF-DMP standardized SNF HF care using HF practice guidelines and performance measures and was delivered by a HF nurse advocate (HFNA). The HFNA directed a 7- component intervention focused on optimizing HF disease management through the following: documentation of EF, symptom and activity assessment, weights 3 times a week with dietary surveillance, recommendations for medication titration, patient/caregiver education, discharge instructions, and 7-day post- SNF discharge follow-up. This sub-group analysis examined patients discharged from hospital to SNF with a primary hospital discharge diagnosis of HF (n=125). The primary outcome was a composite of all-cause hospitalization, emergency department visits, and mortality at 60 days post-SNF admission. The etiology (HF related, non-HF cardiovascular (CV) related, or "other") of the first event was adjudicated by a Clinical Endpoints committee that was blinded to treatment group. Secondary outcomes were the composite outcome at 30 days, and change in health status and self-management from baseline to 60 days measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Self-care of HF Index (SCHFI).
RESULT(S): Of the 125 patients with a primary hospital discharge diagnosis of HF, 50were in the HF-DMP and 75 in UC. Overallmean age was 79+/-10, 53% were women, mean EF was 46+/-15%. At 60 days, the rate of the composite outcome was lower in the HF-DMP group (30%) compared to UC (52%) (p=0.02). Adjudicated events in the HF-DMP group revealed one HF related event, one CV related event, and 12 events classified as "other" within 60 days. In contrast, the UC group had 12 HF related events, 5 CV related events, and 19 events classified as "other" within 60 days. The rate of the composite outcome at 30 days for the HFDMP group was 18% versus 31% in the UC group (p=0.11). Change in KCCQ and SCHFI measures were not significantly different between groups at 60 days.
CONCLUSION(S): Patients with a primary hospital discharge diagnosis of HF who received HF-DMP while receiving rehabilitation in a SNF had lower rates of the composite outcome at 60 days and less HF related events. Standardized HF management during SNF stays may be particularly important for patients with a primary discharge diagnosis of HF